First Tracks Biotherapeutics is trading at $31.34, down 5.84%, with no clear catalyst identified. - It was down 1.89% at the October 2 close; no new company announcement explaining the October 5 decline appeared in searched sources. - The latest company-specific items surfaced were older business updates, including its August 12 second-quarter results. - Major indexes were mixed: the Nasdaq was up 0.73% and the S&P 500 up 0.34%, so broad market weakness does not clearly account for the decline.